Therapeutic Advances in Medical Oncology · 2021 · 24 citations · 26 references
MedicineMolecular GeneticsOncologyCancer GeneticsMolecular OncologyNeoplasiaGastrointestinal Stromal TumorsMalignant NeoplasmsMolecular Classification Of TumorsOncogene MutationsReceptor Tyrosine Kinase OncogenesTumor ClassificationDisease PrognosticationGenetic Prognostic MarkersMetastatic Gastrointestinal Stromal TumorsMolecular Prognostic MarkersMutation-based PrognosticationOncogenic Receptor Tyrosine Kinase MutationsPrognostic VariablesRecurrence-free Survival
Background: Although the gastrointestinal stromal tumor (GIST) genotype is not currently included in risk-stratification systems, a growing body of evidence shows that the pathogenic variant (PV) type and codon location hold a strong prognostic influence on recurrence-free survival (RFS). This information has particular relevance in the adjuvant setting, where an accurate prognostication could help to better identify high-risk tumors and guide clinical decision-making. Materials and Methods: Between January 2005 and December 2020, 96 patients with completely resected GISTs harboring a KIT proto-oncogene receptor tyrosine kinase ( KIT) exon 11 PV were included in the study. We analyzed the type and codon location of the PV according to clinicopathological characteristics and clinical outcome; the metastatic sites in relapsed patients were also investigated. Results: Tumors harboring a KIT exon 11 deletion or deletion/insertion involving the 557 and/or 558 codons, showed a more aggressive clinical behavior compared with tumors carrying deletion/deletion/insertion in other codons, or tumors with duplication/insertion/single-nucleotide variant (SNV) (7-year RFS: 50% versus 73.1% versus 88.2%, respectively; p < 0.001). Notably, among 18 relapsed patients with 557 and/or 558 deletion or deletion/insertion, 14 patients (77.8%) harbored deletions simultaneously involving 557 and 558 codons, while only 4 patients (22.2%) harbored deletions involving only 1 of the 557/558 codons. Thus, when 557 or 558 deletions occurred separately, the tumor showed a prognostic behavior similar to the GIST carrying deletions outside the 557/558 position. Remarkably, patients with GISTs stratified as intermediate risk, but carrying the 557/558 deletion, showed a similar outcome to the high-risk patients with tumors harboring deletions in codons other than 557/558, or duplication/insertion/SNV. Conclusion: Our data support the inclusion of the PV type and codon location in routine risk prediction models, and suggest that intermediate-risk patients whose GISTs harbor 557/558 deletions may also need to be treated with adjuvant imatinib like the high-risk patients.
26
Gain-of-Function Mutations of c- <i>kit</i> in Human Gastrointestinal Stromal Tumors
Seiichi Hirota, Koji Isozaki, Y Moriyama et al. · Science · 1998 · 4.5K citations
Molecular Subtypes of<i>KIT/PDGFRA</i>Wild-Type Gastrointestinal Stromal Tumors
Sosipatros A. Boikos, Alberto S. Pappo, J. Keith Killian et al. · JAMA Oncology · 2016 · 407 citations · Full text
Javier Martín‐Broto, Andrés Poveda, Antonio Llombart‐Bosch et al. · Journal of Clinical Oncology · 2005 · 350 citations · Full text